Treatment of the idiopathic inflammatory myopathies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10385382" target="_blank" >RIV/00216208:11110/18:10385382 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023728:_____/18:N0000089

Výsledek na webu

<a href="https://catalog.loc.gov/vwebv/holdingsInfo?searchId=2393&recCount=25&recPointer=16&bibId=19988562" target="_blank" >https://catalog.loc.gov/vwebv/holdingsInfo?searchId=2393&recCount=25&recPointer=16&bibId=19988562</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment of the idiopathic inflammatory myopathies

Popis výsledku v původním jazyce

Treatment of idiopathic inflammatory myopathies (IIMs) is challenging, because these disorders are rare with heterogeneous clinical manifestations and incompletely understood aetiopathogenesis. There have been only a few randomized controlled clinical trials (RCT), often involving small numbers of patients; therefore treatment strategies are mostly empirical. Management of IIMs should be multidisciplinary and tailored to disease activity and clinical phenotype of a given patient. The goal is to improve muscle strength and to supress extramuscular manifestations of the disease, while minimizing the risk of complications. Pharmacotherapy is the cornerstone of disease management, with the exception of sIBM, which is typically treatment resistant. Exercise is recommended from early disease stages. Side effects of treatment should be carefully monitored.

Název v anglickém jazyce

Treatment of the idiopathic inflammatory myopathies

Popis výsledku anglicky

Treatment of idiopathic inflammatory myopathies (IIMs) is challenging, because these disorders are rare with heterogeneous clinical manifestations and incompletely understood aetiopathogenesis. There have been only a few randomized controlled clinical trials (RCT), often involving small numbers of patients; therefore treatment strategies are mostly empirical. Management of IIMs should be multidisciplinary and tailored to disease activity and clinical phenotype of a given patient. The goal is to improve muscle strength and to supress extramuscular manifestations of the disease, while minimizing the risk of complications. Pharmacotherapy is the cornerstone of disease management, with the exception of sIBM, which is typically treatment resistant. Exercise is recommended from early disease stages. Side effects of treatment should be carefully monitored.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Myositis

ISBN

978-0-19-875412-1

Počet stran výsledku

10

Strana od-do

171-180

Počet stran knihy

186

Název nakladatele

Oxford University Press

Místo vydání

Oxford

Kód UT WoS kapitoly

—